Up-Regulation of SH3TC2 Induced by YTHDF1 Predicts Poor Outcome and Facilitates Cell-Cycle Progress in Colorectal Cancer

Figure 2

Survival analysis based on the GEPIA database uncovers that SH3TC2 is associated with patient prognosis in 4 human cancer types. (a) High expression of SH3TC2 was associated with poor patient DFS in COAD, , HR = 2.2, n (high) = 135, and n (low) = 135. (b) High level of SH3TC2 predicted worse patient DFS in mesothelioma (MESO), , HR = 2.3, n (high) = 41, and n (low) = 38. (c) High SH3TC2 expression indicated undesirable patient DFS in PAAD, , HR = 1.7, n (high) = 88, and n (low) = 88. (d) SH3TC2 was a risk factor for unfavorable patient DFS in READ, , HR = 4.0, n (high) = 46, and n (low) = 46. (e) Crossanalysis showed that SH3TC2 was abnormally expressed in 3 cancers (COAD, PAAD, and READ) and significantly correlated with DFS of patients. (f) The relationship between SH3TC2 expression and patient DFS in COAD and PAAD, , n (high) = 224, and n (low) = 223. (g) The relationship between SH3TC2 expression and patient DFS in PAAD and READ, , n (high) = 133, and n (low) = 133. (h) High SH3TC2 expression indicated worse patient DFS in COAD and READ,  = 9.1E − 5, HR = 2.4, n (high) = 181, and n (low) = 181.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)